Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024. In the quarter to June 2026, revenue grew 466.4%, EPS grew 34.7%, free cash flow grew 9.97% and total debt fell 62.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KYMR
Kymera Therapeutics, Inc. (KYMR) Altman Z-score
Kymera Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is 23.22, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 23.22 | 11.88 |
| FY2024 | 11.35 | 7.85 |
| FY2023 | 3.50 | (2.65) |
| FY2022 | 6.15 | (6.11) |
| FY2021 | 12.25 | 9.22 |
| FY2020 | 3.03 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.45 | — | 0.54 | |
| Retained earnings / total assets | (0.61) | — | −0.86 | |
| EBIT / total assets | (0.20) | — | −0.66 | |
| Market value of equity / total liabilities | 40.30 | — | 24.18 | |
| Sales / total assets | 0.02 | — | 0.02 | |
| Altman Z-score | Safe zone | 23.22 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 9.79 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 61.6× |
| KRYS Krystal Biotech, Inc. compare | 39.0× |
| KYMR Kymera Therapeutics, Inc. | 23.2× |
| AXSM Axsome Therapeutics, Inc. compare | 6.9× |
| TGTX TG Therapeutics, Inc. compare | 6.3× |
| CAI Caris Life Sciences,�Inc. compare | 3.5× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 3.0× |
| CYTK Cytokinetics, Incorporated compare | −2.0× |
| ABVX Abivax SA Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets